Photo: Abdulai Sayni / Unsplash. Illustrative image; no endorsement implied.
Health Content Works | Evidence reviewed September 2026
Author and human reviewer: David L. Carpenter, BSN, RN — licensed Registered Nurse; 10 years of nursing practice and 24 years of healthcare experience. Read our editorial and AI-use standards.
Tirzepatide and semaglutide are two of the most effective medications currently used for chronic weight management. They are often discussed as if one is simply a stronger version of the other, but that misses important differences in mechanism, FDA-approved indications, dosing options, evidence, and individual response.
The short version: in the SURMOUNT-5 randomized head-to-head trial, tirzepatide produced greater average weight loss than injectable semaglutide at the doses studied. That finding is strong evidence for that specific comparison—but it does not mean tirzepatide is automatically the better medication for every person.
What is the difference between tirzepatide and semaglutide?
Semaglutide is a GLP-1 receptor agonist. Tirzepatide activates both GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptors. Both can reduce appetite and energy intake and are used alongside nutrition, physical activity, and other components of obesity treatment.
For chronic weight management, semaglutide is marketed as Wegovy and tirzepatide as Zepbound. The same active ingredients are also sold under other brand names for different indications, so brand names and approved uses should not be treated as interchangeable.
What did the direct head-to-head trial find?
The strongest direct comparison is SURMOUNT-5, a phase 3b, open-label randomized trial involving 751 adults with obesity who did not have type 2 diabetes. Participants received the maximum tolerated dose of tirzepatide (10 or 15 mg weekly) or semaglutide (1.7 or 2.4 mg weekly) for 72 weeks.
At week 72, the least-squares mean change in body weight was -20.2% with tirzepatide and -13.7% with semaglutide. Mean waist circumference fell 18.4 cm with tirzepatide and 13.0 cm with semaglutide. Participants assigned to tirzepatide were also more likely to reach weight-loss thresholds of at least 10%, 15%, 20%, and 25%.
The most common adverse events in both groups were gastrointestinal, generally mild to moderate, and occurred most often during dose escalation.
The limitation that matters in 2026
SURMOUNT-5 did not test every semaglutide option now available. It compared tirzepatide with injectable semaglutide at a maximum tolerated dose of 1.7 or 2.4 mg weekly. Since then, the FDA has approved additional Wegovy formulations and dosing options, including oral Wegovy and a higher-dose injectable semaglutide option. The SURMOUNT-5 percentages therefore should not be presented as a direct comparison between tirzepatide and every current Wegovy formulation.
This is a good example of why obesity-medication comparisons need dates and dose context. A study can remain valid while becoming incomplete as treatment options evolve.
Does greater average weight loss mean tirzepatide is always the better choice?
No. Average trial results describe groups, not guarantees for individuals. Some people respond extremely well to semaglutide. Others respond better to tirzepatide, tolerate one drug better than the other, or have insurance, access, dosing, or medical considerations that change the decision.
A medication choice can reasonably depend on several factors:
- Weight-loss goals and prior response: SURMOUNT-5 supports greater average weight reduction with the tirzepatide regimen studied.
- Cardiovascular disease: Wegovy has an FDA-approved indication to reduce cardiovascular death, heart attack, and stroke in adults with established cardiovascular disease and overweight or obesity.
- Obstructive sleep apnea: Zepbound has an FDA-approved indication for moderate to severe obstructive sleep apnea in adults with obesity, used with reduced-calorie nutrition and increased physical activity.
- Liver disease: Wegovy gained an FDA indication in 2025 for certain patients with MASH, adding another condition-specific reason that may matter clinically.
- Route and dosing preference: current Wegovy options include injection and an oral formulation, while Zepbound is administered subcutaneously.
- Tolerability: nausea, vomiting, diarrhea, constipation, abdominal symptoms, and other gastrointestinal effects can influence the practical choice.
- Coverage and cost: the clinically preferred medication may not be the medication a person can consistently obtain.
What about cardiovascular outcomes?
This is an area where weight-loss percentage and proven clinical outcomes should be kept separate. Semaglutide has direct cardiovascular-outcomes evidence in adults with established cardiovascular disease and overweight or obesity, and the FDA approved Wegovy to reduce major cardiovascular events in that population.
SURMOUNT-5 was designed primarily to compare weight reduction and waist circumference, not to determine which drug prevents more heart attacks, strokes, or cardiovascular deaths. Post hoc analyses can estimate cardiovascular risk changes, but modeled risk is not the same as a randomized cardiovascular-outcomes trial.
Therefore, it is reasonable to say that tirzepatide produced greater weight loss in SURMOUNT-5. It is not reasonable to convert that result into a proven claim that tirzepatide prevents more cardiovascular events than semaglutide.
What about sleep apnea?
In December 2024, the FDA approved Zepbound for moderate to severe obstructive sleep apnea in adults with obesity. That indication is clinically important because it is based on outcomes related to sleep apnea rather than simply assuming that weight loss will improve every obesity-related condition to the same degree.
A person with obesity and clinically significant obstructive sleep apnea may therefore have a different medication discussion than someone whose primary goal is weight reduction alone.
Are side effects very different?
The two medications share many gastrointestinal adverse effects. In SURMOUNT-5, gastrointestinal events were the most common adverse events in both groups and were generally mild to moderate, especially during dose escalation.
Both drug classes also carry important prescribing warnings and contraindications. Their FDA labels should be used for current safety information rather than relying on social media summaries. Both have boxed warnings regarding thyroid C-cell tumors based on rodent findings and are contraindicated in people with a personal or family history of medullary thyroid carcinoma or MEN 2.
Medication changes, dose escalation, persistent vomiting, severe abdominal symptoms, dehydration, pregnancy planning, or significant changes in other health conditions should be discussed with the prescribing clinician.
What about muscle and lean mass?
Large weight losses from either medication can include some loss of lean mass. Lean mass is not identical to skeletal muscle, and body-composition studies do not automatically tell us what happened to strength or function.
For a deeper review of protein and muscle preservation during GLP-1-associated weight loss, see our article How Much Protein Do You Need on Wegovy, Zepbound, or Other GLP-1 Medications? and the companion GLP-1 Muscle Preservation Checklist.
A practical way to compare them
Instead of asking only, “Which drug causes more weight loss?” a more useful discussion is:
- What outcome matters most to me—weight, cardiovascular risk, sleep apnea, liver disease, glucose control, function, or several of these?
- Which formulation and dose has actually been studied for that outcome?
- Which medication can I obtain consistently?
- Which one can I tolerate long enough to benefit?
- How will we monitor nutrition, strength, gastrointestinal symptoms, hydration, and other medications while weight changes?
Bottom line
Tirzepatide produced substantially greater average weight loss than injectable semaglutide 1.7/2.4 mg in SURMOUNT-5. That is high-quality direct evidence for the comparison the trial actually tested.
But the modern choice between Zepbound and Wegovy is more nuanced than one percentage. Current Wegovy options have evolved since SURMOUNT-5, and each medication has condition-specific evidence and FDA-approved indications that may matter more than average weight loss for a particular patient.
The best medication decision is individualized and should be made with a qualified prescribing clinician using current labeling, medical history, treatment goals, tolerability, and access.
About the author
David L. Carpenter, BSN, RN is a licensed Registered Nurse with 10 years of nursing practice and 24 years of healthcare experience. He is the founder and editor of Health Content Works, with a focus on evidence-based education about obesity, GLP-1 medications, nutrition, exercise, metabolic health, and practical healthy living.
David also brings lived experience with obesity, weight loss, and GLP-1 treatment. His personal experience helps shape the practical questions explored by Health Content Works, while medical conclusions are grounded in research, clinical guidance, and authoritative sources.
References
1. Aronne LJ, et al. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity. N Engl J Med. 2025;393:26-36. PMID: 40353578. DOI: 10.1056/NEJMoa2416394.
2. U.S. Food and Drug Administration. FDA Approves First Treatment to Reduce Risk of Serious Heart Problems Specifically in Adults with Obesity or Overweight. March 8, 2024.
3. U.S. Food and Drug Administration. FDA Approves First Medication for Obstructive Sleep Apnea. December 20, 2024.
4. U.S. Food and Drug Administration. Wegovy prescribing information and FDA labeling database, current through 2026.
5. U.S. Food and Drug Administration. Zepbound prescribing information and FDA labeling database, current through 2026.
6. Abdalla M, et al. Comparative Efficacy and Safety of Tirzepatide Versus Semaglutide for Obesity: A Systematic Review. 2026. PMID: 42732434.
This article is for general education and is not individualized medical advice. Prescription medication decisions should be made with a qualified healthcare professional.